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Abstract: Performance Status (PS) variability is a powerful tool to evaluate overall condition,
treatment needs and survival chances of cancer patients. Traditionally, its assessment has relied on the
experience of oncologists when interpreting results of clinical tests and when interviewing the patients.
Meanwhile, consumer-level activity trackers have obtained good results in behavior-change oriented
intervention trials and Fitbit devices have demonstrated enough reliability to provide objective data
related to physical activity, but the clinical possibilities of the data collected has been neglected.
This work presents a system design for ubiquitous assessment of PS by means of objective and
quantifiable data from different sources: medical history, self-reported quality-of-life questionnaires
and a commercial activity tracker Fitbit Alta HR. The system proposed aims to contextualize and
model the recovery process of breast cancer patients during chemotherapy treatment.
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1. Introduction
Performance Status (PS) variability is a powerful tool to evaluate overall condition, treatment
needs and survival chances of cancer patients. It measures the ability of patients to perform the
activities of daily living by comprehending several dimensions of the disease, such as physical activity
performance, quality of life and the toxicity levels of the treatment [1]. The Eastern Cooperative
Oncology Group (ECOG) [2] and Karnofsky Performance Status (KPS) [3] scales have served this
purpose for decades and they are still widely used among oncologists.
However, the ambiguity and broad dimensions rooted in the definition of PS scales make them
prone to subjectivity and interpretation, forcing oncologists to evaluate PS mainly from personal
interviews with patients that may be under severe conditions of pressure, anxiety and uncertainty,
along with the secondary effects of the treatment [4,5]. This subjectivity and the tight relationship of
physical activity with PS [6] are the main reasons for introducing activitytrackers when monitoring the
recovery of cancer patients.
Several clinical trials have already used wearable activity trackers in oncology trials, specially
with breast cancer patients and survivors [7]. Research-grade monitors like Actigraph GT3X+ or
the ActivPAL were the most used, but there is a growing trend in including consumer-level activity
trackers like Fitbit devices due to their popularity, reliability and cost-effectiveness. Fitbit devices have
been successfully used within the context of behavior change interventions such as healthy lifestyle
promotion, physical activity raise and weight control in population with different conditions such
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as breast cancer survivors, pregnant moms and patients with type 2 diabetes mellitus [8–10], but the
possible clinical relevance of the data collected is still being neglected. Despite the subtle differences
interpreting results across the literature, most of them point out that Fitbit devices may provide reliable
objective data referred to physical activity, especially within free living environments [11–14].
All this lays down the basis for the system proposed, where commercial activity trackers, namely
Fitbit, provide ubiquitous, objective and quantifiable measures of the physical activity of breast cancer
patients, thus aiming to reduce biases and subjectivity in PS evaluation.
2. State of the Art
In previous work we addressed automatic monitoring of PS from a broad perspective of cancer
patients [15]. In this work we focus in breast cancer patients since they have been widely studied with
research-oriented and commercial activity trackers. According to Gresham et al., they represented
the 65% of the total amount of oncology trials related to activity trackers between 2005 and 2016 [7].
This over-representation of breast cancer (both patients and survivors) across oncology trials matches
their high involvement and implication in their treatment and recovery. Moreover, the overall good
acceptance reported (82% median adherence) is similar to the those reported in more recent studies
promoting healthy lifestyle behavior in breast cancer patients (92.13% adherence) [16] and survivors
(88.13% adherence) [8]. For these reasons, breast cancer patients reveal themselves as the most
appropriate group to study the ubiquitous assessment of PS.
Regarding consumer-level activity trackers, Fitbit devices reported better reliability than the one
we used in previous work [15,17], however, despite their promising results and growing acceptance in
clinical trials, “discretion should be used when considering the use of Fitbit devices as an outcome
measurement tool in research or to inform health care decisions” [17]. In this section we discuss some
of the most relevant contributions related to the reliability provided by Fitbit devices: steps count,
energy expenditure, physical activity levels, heart rate and sleep tracking.
2.1. Fitbit’s Steps Count
Steps count is one of the main variables used for measuring physical activity levels, even in
oncology trials [7,18]. The good accuracy reported by wrist-worn Fitbit devices in controlled and
free-living settings makes this activity trackers ideal for the proposed system [17]. Some trials included
in the systematic review of Feehan et al. [17] represent the conditions to be encountered when assessing
PS in breast cancer patients, for example, a trial with 22 prostate cancer survivors monitored with Fitbit
One during 7 days under free-living settings found no significant differences in steps count compared
to GT3X+ (r = 0.94) [12]; and 22 healthy women monitored with Fitbit Flex during 7 days found no
statistical difference in daily steps count compared GT3X+ [19].
On the other hand, the work of Ummels et al. rejected the validity of 9 commercial activity
trackers (Fitbit One and Fitbit Flex among them) for 130 patients with a chronic disease [20]. However,
the activities described in the protocol were most of them homework tasks, and very short in duration
(19 activities in 28 to 33 min). The short-lasting activities and the implicit low-consistent patterns
of movement within them (e.g., 1 min of simulated cleaning of windows, 7 m of walking weaving
around cones) may have over-hindered the steps count for the tested devices; besides, not including
research-oriented activity trackers impedes any comparison to trials relying on validated monitors like
GT3X+. Other works show that the validation problem of consumer-level devices does not seem to
be rooted in the chronic condition of patient, but in their overall mobility [17], for example, Alharbi
et al. obtained a very high correlation of Fitbit Flex steps count compared to GT3X+ (r = 0.95) in a
community-based phase III cardiac rehabilitation population [21].
2.2. Fitbit’s Energy Expenditure & Physical Activity Levels
There is agreement on Fitbit overestimating energy expenditure and misclassifying physical
activity levels (sedentary, light, moderate, vigorous) when compared to GT3X+, especially for moderate
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and vigorous activity [12,13,17,19,22]. Winfree et al. have successfully tackled this issue with a
Naïve-Bayes classification model that leverages Fitbit Flex data as its input that removes statistical
differences between GT3X+ MVPA (moderate-to-vigorous physical activity) and Fitbit Flex MVPA [23].
This approach makes shows that it is possible to extract meaningful knowledge from the original data
provided by Fitbit, so this deserves to be studied along with reliable clinical data.
2.3. Fitbit’s Heart Rate & Sleep Tracking
Regarding other measures of Fitbit such as heart rate, there is clear agreement in its low reliability and
high sensitivity to artifacts and sensor displacement, so this data should be interpreted carefully [11,17,24].
Sleep tracking is also reported to be systematically overestimated [17], thus it needs to be addressed
with caution too.
3. System Design
This section presents a system design based in previous work [15], adapting it to Fitbit devices
and breast cancer patients. Figure 1 presents the system design for the experiment proposed. Patients
will participate voluntarily through informed consent and always under the protection of General
Data Protection Regulation (GDPR) guidelines; data will be anonymized and stored securely within a
remote sever located in our faculty laboratory.
Figure 1. System design.
3.1. Data Sources
There are three main data sources: medical history, self-reported quality-of-life questionnaires
and the Fitbit Cloud, which hosts the data collected by a Fitbit Alta HR activity tracker. On the left
of Figure 1, there are data from medical records, the most important part of our system: the experts’
knowledge. Clinical PS evaluations of patients will be the main outcome to measure; treatment details,
blood tests and incidences will be gathered too during the recovery process to remove factors of
confusion like anemia—which is related to sensations of fatigue and tiredness—-. The frequency of
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these data will depend on the drugs and treatment administered, varying among 7, 14 or 21 days.
This data needs introduced into our database manually through web forms connected to a secure web
service.
Patient will report its demographics in the start of the trial when registering. They will report their
quality of life with the QLQ-C30 questionnaire at the beggining, middle and end of their treatment to
contrast self-reported functional and symptom scales. This data will be retrieved by using web forms
connected to our database by a web service. The frequency of this data is even lower than medical
records, but this methodology mimics previous intervention trials to avoid overwhelming patients
with constant questionnaires.
Fitbit Alta HR will monitor the activity of each patient during the entire chemotherapy treatment
(minimum of 12 weeks). This device measures every variable discussed in Section 2, so that will
contextualize the data from medical history and questionnaires in an objective and quantifiable way.
The sampling frequency of the device is very high (compared to the rest of the data) and it uploads all
the data directly to the Fitbit Cloud. This cloud provides a REST API that allows data to be collected in
our database with granularity from seconds (heart-rate) to minutes (steps count, energy expenditure,
physical activity levels, sleep tracking).
3.2. Data Security
Security of patients is the most important issue while handling their sensitive data, therefore, this
subsection explains the conditions in which data is stored and collected to meet security standards
under GDPR legislation. To ensure physical security the server will be placed at the CITIC-UGR
Research Center in the University of Granada (Granada, Spain). Access to the center will be restricted
to university personnel, and besides, the server will be located in a room with limited access to the
researchers involved in the project. The server will not be used by third persons in a direct nor indirect
way. The information stored in the server will be encrypted so that there is no possible way to access
the data, not even by stealing the hard drives or by other means. The database collecting the data
will have limited access, only available to the research team. Any possible communication between a
secure web environment (HTTPS) and the database will be made locally so that information is not
visible nor accessible from the outside. Moreover, to ensure maximum security of external access, a
firewall will limit the number of available ports for connections, only enabling ports 22 (SSH) and 443
(HTTPS). Both ports will be secured by OpenSSL libraries that ensure the confidentiality and integrity
of the information by encrypting data exchanges with the outside.
4. Discussion
This work proposes a system to overcome the limitations of subjective PS evaluation by combining
ubiquitous and objective physical activity data, clinically validated self-reported questionnaires
(QLQ-C30) and the clinical data within medical records (e.g., PS assessed by oncologists, blood tests,
symptoms, etc.). The consistency of Fitbit devices when measuring steps count, and the possibilities
offered by energy expenditure and sleep tracking, support a more objective assessment of PS. Moreover,
breast cancer patients reveal themselves as a trustworthy group to test the system proposed due to the
high adherence and acceptance outcomes along activity-tracker related trials [7].
The inclusion of continuous and ubiquitous data of each patient will provide the ability to study
it from a more individual perspective, focusing on tendencies and on the evolution of recovery across
time. Diagnostic data will remain always as source of truth despite the critiques of PS scales, since the
expert’s knowledge is what we are aiming to support. The vision of this work is to ultimately provide
oncologists with decision support systems for better assistance of cancer patients with affordable tools
like commercial activity trackers.
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5. Conclusions
Performance status variability is a powerful tool to evaluate treatment needs and survival chances
of cancer patients. Traditionally, its assessment has relied on personal interviews with patients and
the experience of oncologists. Consumer-level activity trackers have managed good results among
behavior-change oriented intervention trials, but the clinical possibilities of the data collected has
been neglected. Fitbit devices have demonstrated enough reliability to supply objective data during
the entire recovery process of breast cancer patients. This work presents a system design to evaluate
performance status by means of objective and quantifiable data from different sources: medical history,
self-reported quality-of-life questionnaires and continuous monitoring of a Fitbit Alta HR activity
tracker. Its future implementation will allow us to extract the relevance of each variable in performance
status assessment, and to model the recovery process of breast cancer patients during chemotherapy.
A trial design with breast cancer patients and the system proposed has been approved by the Ethics
Committee of the Virgen de las Nieves Hospital.
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